GILD Stock Recent News

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (GILD -2.54%) took some hits on Tuesday. Investors traded it down by more than 2%, comparing unfavorably to the 0.6% gain of the benchmark S&P 500 (^GSPC 0.55%).

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company's investigational HIV drugs. The FDA's clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.

(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday. (Reporting by Sneha S K; Editing by Leroy Leo)

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.'s GILD New Drug Application (NDA) submissions for lenacapavir — the company's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Medical Officer Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Good morning, everyone.